Concepedia

Douglas Wight

DW

Statistics

Publications

3

Citations

133

H-Index

3

Active since

2014

Affiliations

Vertex Pharmaceuticals (Canada)(Current)

Montreal Heart Institute

Capital Cardiology Associates

Piedmont Atlanta Hospital

Douglas Wight is an author at Vertex Pharmaceuticals (Canada) specializing in pharmacology, clinical pharmacology, and nasal spray formulations.

ORCID

Publications per year

2014–2022

3

Publications

3

Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm

Bruce S. Stambler, Paul Dorian, Philip T. Sager et al. · Journal of the American College of Cardiology · 2018 · 70 citations · Full text

, , +17

First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)

Bruce S. Stambler, Francis Plat, Philip T. Sager et al. · Circulation Arrhythmia and Electrophysiology · 2022 · 39 citations · Full text

, , +17

Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin

Ling He, Prachi Wickremasingha, James Lee et al. · Diabetes Research and Clinical Practice · 2014 · 24 citations

, , +6

1–3 of 3